Clinical Trial Update: A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical study of YY-20394 in patients with relapsed/refractory Follicular Lymphoma is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• YY-20394

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Follicular Lymphoma | Phase 2 | Status: UNKNOWN